本研究调查超声 (US) 引导射频消融 (RFA) 治疗局部复发性甲状腺乳头状癌 (PTC) 的长期疗效和安全性。我们回顾性分析了 39 名连续患者，其中 61 例局部复发性 PTC（14 名男性，25 名女性） ；平均±标准差年龄，52.8±16.7岁；范围21-92岁），在2008年9月至2012年4月期间接受了美国引导的具有治疗目的的RFA。该亚组由24名患有37例复发性PTC的患者组成，并进行了随访至少分别分析了10年。所有患者均在 RFA 后 1、3、6 和 12 个月时随访超声病变大小和甲状腺球蛋白 (Tg) 水平的变化，此后每 6-12 个月随访一次。在随访期间记录任何并发症。使用 Kaplan-Meier 估计值评估无复发生存率 (RFS)。对患者进行至少 10 年随访的长期结果进行评估。随访期为 7 至 180 个月（中位 133 个月）。 39 名患者在 3 年、5 年和 10 年的 RFS 率分别为 86.8%、75.5% 和 60.6%。随访10年以上的24例37个复发PTC患者中，体积缩小率为99.9%（范围96%-100%），肿瘤完全消失率为91.9%。平均血清 Tg 水平也显着下降，从消融前的 2.66 ± 86.5 mIU/L 降至最终随访时的 0.43 ± 0.73 mIU/L (P < 0.001)。 24 名患者中有 14 名 (58.3%) 在最后一次随访时 Tg 水平检测不到（低于 0.08 mIU/L）。 10 年随访期间，未观察到危及生命或迟发的并发症。整个随访期间的高 RFS，其有效性和安全性持续超过 10 年，支持超声引导下 RFA 作为局部控制的宝贵选择复发性 PTC 的数量。版权所有 © 2024 韩国放射学会。

This study investigates the long-term efficacy and safety of ultrasound (US)-guided radiofrequency ablation (RFA) for treating locally recurrent papillary thyroid cancer (PTC).We retrospectively analyzed 39 consecutive patients with 61 locally recurrent PTCs (14 males, 25 females; mean ± standard deviation age, 52.8 ± 16.7 years; range 21-92 years) who underwent US-guided RFA with curative intent between September 2008 and April 2012. A subgroup of 24 patients with 37 recurrent PTCs who had a follow-up of at least 10 years were analyzed separately. All patients were followed for changes in lesion size on US and thyroglobulin (Tg) levels at 1, 3, 6, and 12 months after RFA, with follow-up every 6-12 months thereafter. Any complications were documented during the follow-up period. Recurrence-free survival (RFS) rates were assessed using Kaplan-Meier estimates. Long-term outcomes were evaluated in patients with follow-up of at least 10 years.The follow-up period ranged from 7 to 180 months (median 133 months). The RFS rates for the 39 patients at 3, 5, and 10 years were 86.8%, 75.5%, and 60.6%, respectively. Among the 24 patients with 37 recurrent PTCs followed for more than 10 years, the volume reduction rate was 99.9% (range 96%-100%), and the complete tumor disappearance rate was 91.9%. The mean serum Tg level also decreased significantly, from 2.66 ± 86.5 mIU/L before ablation to 0.43 ± 0.73 mIU/L (P < 0.001) at the final follow-up. In 14 (58.3%) of the 24 patients, Tg levels were undetectable (below 0.08 mIU/L) at the last follow-up. No life-threatening or delayed complications were observed during the 10-year follow-up period.The high RFS throughout the follow-up period, with efficacy and safety lasting beyond 10 years, supports US-guided RFA as a valuable option for local control of recurrent PTCs.Copyright © 2024 The Korean Society of Radiology.